NCT05249556View on ClinicalTrials.gov

Double-blind, Randomized, Placebo-controlled Trial of Ganaxolone in CDKL5 Deficiency Patients 6 Months to Less Than 2 Years Old

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

March 31, 2027

Conditions
CDKL5 Deficiency Disorder
Interventions
DRUG

Ganaxolone

Ganaxolone

DRUG

Placebo

Placebo (for ganaxolone)

Sponsors
All Listed Sponsors
lead

Marinus Pharmaceuticals

INDUSTRY

NCT05249556 - Double-blind, Randomized, Placebo-controlled Trial of Ganaxolone in CDKL5 Deficiency Patients 6 Months to Less Than 2 Years Old | Biotech Hunter | Biotech Hunter